• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Azitra Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    2/20/25 4:15:27 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    false 0001701478 0001701478 2025-02-20 2025-02-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 20, 2025

     

    AZITRA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41705   46-4478536

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    21 Business Park Drive, Branford, Connecticut   06405
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 646-6446

     

    Not Applicable
    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol   Name of each exchange on which registered
    Common Stock, $0.0001 par value   AZTR   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging Growth Company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On February 20, 2025, Azitra, Inc. (the “Company”), convened a special meeting of stockholders (the “Special Meeting”). Proxies had been submitted by stockholders representing over one-third of the shares of the Company’s common stock outstanding and entitled to vote, which constituted a quorum. At the Special Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the proxy statement.

     

    The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Special Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.

     

    Proposal No. 1. Stockholders approved an amendment (as set forth on Exhibit A to the Company’s proxy statement) to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company’s issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-seven (1:7), with the exact ratio within such range and with such reverse stock split to be effectuated at such time and date, if at all, to be determined by the Board of Directors. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    2,435,494   657,144   342   0

     

    Proposal No. 2. Stockholders approved to adjourn the Special Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of the foregoing proposal. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    2,476,620   614,341   2,019   0

     

    Although Proposal No. 2 was approved by the Company’s stockholders, the Board of Directors did not elect to adjourn the meeting as Proposal No. 1 was approved.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 20, 2025 AZITRA, INC.
       
      /s/ Francisco D. Salva
      Francisco D. Salva
      Chief Executive Officer

     

     

     

    Get the next $AZTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    SEC Filings

    View All

    Azitra Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/23/26 9:00:24 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/13/26 5:26:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Azitra Inc

    DEFA14A - Azitra, Inc. (0001701478) (Filer)

    3/5/26 4:36:04 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

    BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As previously reported, on Octobe

    3/13/26 5:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

    BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026. About AzitraAzitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12,

    3/5/26 4:30:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

    BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update. FY 2025 and Recent Business HighlightsInitiated Phase 1/2 Trial for ATR-04 program targeting oncology patients with EGFRi-associated rash; presented ATR-04 trial design and update at ASCO 2025Announced positive preclinical data for ATR-01 program, targeting the treatment of ichth

    2/27/26 5:30:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

    4 - Azitra, Inc. (0001701478) (Issuer)

    4/1/24 9:51:59 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Salva Francisco D.

    4 - Azitra, Inc. (0001701478) (Issuer)

    3/20/26 4:30:30 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Whitfill Travis

    4 - Azitra, Inc. (0001701478) (Issuer)

    12/22/25 5:28:27 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Staskey Norm

    4 - Azitra, Inc. (0001701478) (Issuer)

    12/22/25 5:28:23 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    View All

    Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

    BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

    7/11/23 4:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Financials

    Live finance-specific insights

    View All

    Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

    2/24/25 8:30:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

    11/12/24 5:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

    Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

    8/12/24 6:23:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/6/24 4:35:43 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care